The sclerostin story: From human genetics to the development of novel anabolic treatment for osteoporosis

Hormones

Volumn 13, Issue 4, 2014, Pages 476-487

  Yavropoulou, Maria P ^a   Xygonakis, Christos ^a   Lolou, Maria ^a   Karadimou, Fotini ^a   Yovos, John G ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Antibodies; Blosozumab; BPS804; Romosozumab; Sclerostin

Indexed keywords

BLOSOZUMAB; MONOCLONAL ANTIBODY; ROMOSOZUMAB; SCLEROSTIN; ANABOLIC AGENT; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

BONE DISEASE; BONE MASS; CLINICAL STUDY; DRUG EFFICACY; DRUG SAFETY; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOST GENE; VAN BUCHEM DISEASE; ANIMAL; BONE DENSITY; BONE DEVELOPMENT; DRUG DEVELOPMENT; GENETIC MARKER; GENETICS; HAPLORHINI; HYPEROSTOSIS; ISOLATION AND PURIFICATION; MEDICAL GENETICS; MOUSE; PHYSIOLOGY; RAT; SYNDACTYLY;

ANABOLIC AGENTS; ANIMALS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; DRUG DISCOVERY; GENETIC MARKERS; GENETICS, MEDICAL; HAPLORHINI; HUMANS; HYPEROSTOSIS; MICE; OSTEOGENESIS; OSTEOPOROSIS; RATS; SYNDACTYLY;

EID: 84916238585     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1552     Document Type: Review

References (78)

1. Manolagas SC, Jilka RL, 1995 Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332: 305-311.
2. Manolagas SC, 2000 Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115-137.
3. Beighton P, Durr L, Hamersma H, 1976 The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals. Ann Intern Med 84: 393-397.
4. van Bezooijen RL, Roelen BA, Visser A, et al, 2004 Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199: 805-814.
5. Balemans W, Ebeling M, Patel N, et al, 2001 Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537-543.
6. Piters E, Culha C, Moester M, et al, 2010 First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum Mutat 31: E1526-1543.
7. van Bezooijen RL, Svensson JP, Eefting D, et al, 2007 Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22: 19-28.
8. van Lierop AH, Hamdy NA, Hamersma H, et al, 2011 Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 26: 2804-2811.
9. Beighton P, 1988 Sclerosteosis. J Med Genet 25: 200- 203.
10. Hamersma H, Gardner J, Beighton P, 2003 The natural history of sclerosteosis. Clin Genet 63: 192-197.
11. Booth JB, 1982 Medical management of sensorineural hearing loss. Part II: Musculo-skeletal system. J Laryngol Otol 96: 773-795.
12. Tacconi P, Ferrigno P, Cocco L, et al, 1998 Sclerosteosis: report of a case in a black African man. Clin Genet 53: 497-501.
13. Beighton P, Barnard A, Hamersma H, van der Wouden A, 1984 The syndromic status of sclerosteosis and van Buchem disease. Clin Genet 25: 175-181.
14. du Plessis JJ, 1993 Sclerosteosis: neurosurgical experience with 14 cases. J Neurosurg 78: 388-392.
15. Gardner JC, van Bezooijen RL, Mervis B, et al, 2005 Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 90: 6392-6395.
16. Van Buchem FS, Hadders HN, Ubbens R, 1955 An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta radiol 44: 109-120.
17. Van Buchem FS, Hadders HN, Hansen JF, Woldring MG, 1962 Hyperostosis corticalis generalisata. Report of seven cases. Proc K Ned Akad Wet C 65: 205-217.
18. van Buchem FS, 1971 Hyperostosis corticalis generalisata. Eight new cases. Acta Med Scand 189: 257-267.
19. Brunkow ME, Gardner JC, Van Ness J, et al, 2001 Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68: 577-589.
20. Staehling-Hampton K, Proll S, Paeper BW, et al, 2002 A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 110: 144-152.
21. Balemans W, Patel N, Ebeling M, et al, 2002 Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39: 91-97.
22. van Lierop AH, Hamdy NA, van Egmond ME, Bakker E, Dikkers FG, Papapoulos SE, 2013 Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res 28: 848-854.
23. Loots GG, Kneissel M, Keller H, et al, 2005 Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15: 928-935.
24. Vanhoenacker FM, Balemans W, Tan GJ, et al, 2003 Van Buchem disease: lifetime evolution of radioclinical features. Skeletal Radiol 32: 708-718.
25. Lewiecki EM, 2011 Sclerostin: a novel target for intervention in the treatment of osteoporosis. Discov Med 12: 263-273.
26. Yavropoulou MP, Yovos JG, 2007 The role of the Wnt signaling pathway in osteoblast commitment and differentiation. Hormones (Athens) 6: 279-294.
27. Johnson ML, 2004 The high bone mass family--the role of Wnt/Lrp5 signaling in the regulation of bone mass. J Musculoskelet Neuronal Interact 4: 135-138.
28. Ott SM, 2005 Sclerostin and Wnt signaling--the pathway to bone strength. J Clin Endocrinol Metab 90: 6741-6743.
29. Gong Y, Slee RB, Fukai N, et al, 2001 LDL receptorrelated protein 5 (LRP5) affects bone accrual and eye development. Cell 107: 513-523.
30. Little RD, Carulli JP, Del Mastro RG, et al, 2002 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70: 11-19.
31. Boyden LM, Mao J, Belsky J, et al, 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346: 1513-1521.
32. Van Wesenbeeck L, Cleiren E, Gram J, et al, 2003 Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72: 763-771.
33. Li Y, Pawlik B, Elcioglu N, et al, 2010 LRP4 mutations alter Wnt/beta-catenin signaling and cause limb and kidney malformations in Cenani-Lenz syndrome. Am J Hum Genet 86: 696-706.
34. Kato M, Patel MS, Levasseur R, et al, 2002 Cbfa1- independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157: 303-314.
35. Sims NA, Chia LY, 2012 Regulation of sclerostin expression by paracrine and endocrine factors. Clin Rev Bone Miner Metab 10: 98-107.
36. Bellido T, Ali AA, Gubrij I, et al, 2005 Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146: 4577-4583.
37. van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE, 2010 Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 163: 833-837.
38. Gooi JH, Pompolo S, Karsdal MA, et al, 2010 Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone 46: 1486-1497.
39. Robling AG, Niziolek PJ, Baldridge LA, et al, 2008 Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283: 5866-5875.
40. Bonnet N, Ferrari SL, 2010 Exercise and the skeleton: how it works and what it really does. IBMS BoneKEy 7: 235-248.
41. Gaudio A, Pennisi P, Bratengeier C, et al, 2010 Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilizationinduced bone loss. J Clin Endocrinol Metab 95: 2248- 2253.
42. Modder UI, Clowes JA, Hoey K, et al, 2011 Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 26: 27-34.
43. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE, 2008 Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 58: 1674-1686.
44. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R, 2005 Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329: 177-181.
45. Guanabens N, Gifre L, Peris P, 2014 The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid- induced osteoporosis. Curr Osteoporos Rep 12: 90-97.
46. van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M, Papapoulos SE, 2012 Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab 97: E1953-1957.
47. Gifre L, Ruiz-Gaspa S, Monegal A, et al, 2013 Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 57: 272-276.
48. Genetos DC, Yellowley CE, Loots GG, 2011 Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression. PLoS One 6: e17772.
49. Walker EC, McGregor NE, Poulton IJ, et al, 2008 Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res 23: 2025-2032.
50. Walker EC, McGregor NE, Poulton IJ, et al, 2010 Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest 120: 582-592.
51. Yang F, Tang W, So S, de Crombrugghe B, Zhang C, 2010 Sclerostin is a direct target of osteoblast-specific transcription factor osterix. Biochem Biophys Res Commun 400: 684-688.
52. Quach JM, Walker EC, Allan E, et al, 2011 Zinc finger protein 467 is a novel regulator of osteoblast and adipocyte commitment. J Biol Chem 286: 4186-4198.
53. Sims NA, Johnson RW, 2012 Leukemia inhibitory factor: a paracrine mediator of bone metabolism. Growth Factors 30: 76-87.
54. Lorenzo J, 2008 Ephs and ephrins: a new way for bone cells to communicate. J Bone Miner Res 23: 1168-1169.
55. Vincent C, Findlay DM, Welldon KJ, et al, 2009 Proinflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogenactivated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 24: 1434-1449.
56. Drake MT, Srinivasan B, Modder UI, et al, 2010 Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95: 5056-5062.
57. Arasu A, Cawthon PM, Lui LY, et al, 2012 Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab 97: 2027-2032.
58. Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA, 2012 High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res 27: 2592-2602.
59. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD, 2013 Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 24: 489-494.
60. Szulc P, Bertholon C, Borel O, Marchand F, Chapurlat R, 2013 Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. J Bone Miner Res 28: 855-864.
61. Clarke BL, Drake MT, 2013 Clinical utility of serum sclerostin measurements. Bonekey Rep 2: 361.
62. Dawson-Hughes B, Harris SS, Ceglia L, Palermo NJ, 2014 Serum sclerostin levels vary with season. J Clin Endocrinol Metab 99: E149-152.
63. Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M, 2012 Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50: 739-742.
64. Appel H, Ruiz-Heiland G, Listing J, et al, 2009 Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60: 3257-3262.
65. He JW, Yue H, Hu WW, Hu YQ, Zhang ZL, 2011 Contribution of the sclerostin domain-containing protein 1 (SOSTDC1) gene to normal variation of peak bone mineral density in Chinese women and men. J Bone Miner Metab 29: 571-581.
66. Li X, Ominsky MS, Niu QT, et al, 2008 Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. Journal of Bone and Mineral Research 23: 860-869.
67. Winkler DG, Sutherland MK, Geoghegan JC, et al, 2003 Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 6267-6276.
68. Li X, Ominsky MS, Warmington KS, et al, 2009 Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578-588.
69. Ominsky MS, Vlasseros F, Jolette J, et al, 2010 Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25: 948-959.
70. Padhi D, Allison M, Kivitz AJ, et al, 2013 Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. J Clin Pharmacol: doi: 10.1002/jcph.239.
71. McClung MR, Grauer A, Boonen S, et al, 2014 Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370: 412-420.
72. McColm J, Hu L, Womack T, Tang CC, Chiang AY, 2014 Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 29: 935-943.
73. Recker R, Benson C, Matsumoto T, et al, 2014 A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res: doi: 10.1002/jbmr.2351.
74. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ, 2011 Sclerostin stimulates osteocyte support of osteoclast activity by a RANKLdependent pathway. PLoS One 6: e25900.
75. Becker CB, 2014 Sclerostin inhibition for osteoporosis- -a new approach. N Engl J Med 370: 476-477.
76. Evenepoel P, D'Haese P, Brandenburg V, 2014 Romosozumab in postmenopausal women with osteopenia. N Engl J Med 370: 1664.
77. Bostrom KI, Rajamannan NM, Towler DA, 2011 The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ Res 109: 564-577.
78. Viaene L, Behets GJ, Claes K, et al, 2013 Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 28: 3024-3030.